Chapter 34 Gastrointestinal Disease in Systemic Lupus Erythematosus Chi Chiu Mok, MD, FRCP INTRODUCTION Gastrointestinal (GI) manifestations of systemic lupus erythematosus (SLE) are protean. Any part of the GI tract,…
Chapter 48 New Treatments in Systemic Lupus Erythematosus Vasileios C. Kyttaris, MD , George C. Tsokos, MD INTRODUCTION Immunosuppressive therapy, the main treatment modality for severe lupus, has been effective…
Chapter 45 Systemic Steroids Mustafa Al-Maini, MD , Murray Urowitz, MD INTRODUCTION Corticosteroid medications are found in the therapeutic armamentarium of most medical specialties. Rheumatologists have had a long relationship…
Chapter 38 Overlap Syndromes, Mixed Connective Tissue Disease, and Undifferentiated Connective Tissue Disease Robert W. Hoffman, DO INTRODUCTION Classification of the rheumatic diseases continues to be challenging for a number…
Chapter 42 Neonatal Lupus: Clinical Perspectives Anca D. Askanase, MD, MPH , Jill P. Buyon, MD INTRODUCTION Neonatal lupus (NL) is a model of passive autoimmunity; anti-SSA/Ro-SSB/La antibodies (Ab) cross…
Chapter 22D Antibodies to SSA/Ro and SSB/La: Potential Mechanisms of Tissue Injury in Neonatal Lupus-Congenital Heart Block Jill P. Buyon, MD , Robert M. Clancy, PhD PATHOGENESIS: LAYING THE GROUNDWORK…
Chapter 22C Antineuronal Antibodies John G. Hanly, MD INTRODUCTION Autoantibody production is a cardinal feature in the pathogenesis of systemic lupus erythematosus (SLE) and is associated with most of the…
Chapter 22G Anti-Spliceosomal Autoantibodies Edward K.L. Chan, PhD , Carol Peebles, MS, MT , Marvin J. Fritzler, MD, PhD , Minoru Satoh, MD, PhD INTRODUCTION Anti-Sm was one of the…
Chapter 47 Treatment of Antiphospholipid Syndrome Munther A. Khamashta, MD, FRCP, PhD INTRODUCTION Antiphospholipid syndrome (APS) is defined by the development of thrombosis and/or adverse obstetric events in the presence…
